Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives $38.50 Consensus Target Price from Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $38.50.

Several research analysts recently commented on CNTA shares. Wells Fargo & Company lifted their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Oppenheimer upped their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $25.48 on Friday. The company’s fifty day moving average is $25.40 and its 200 day moving average is $22.60. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $30.58. The stock has a market cap of $3.43 billion, a PE ratio of -13.92 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the transaction, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at $3,159,078. This represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares in the company, valued at $1,449,771.75. This trade represents a 40.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 89,961 shares of company stock worth $2,344,878 over the last 90 days. 7.09% of the stock is owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals during the second quarter valued at approximately $218,000. American Century Companies Inc. raised its stake in Centessa Pharmaceuticals by 3.5% during the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after buying an additional 37,954 shares during the last quarter. Federated Hermes Inc. bought a new stake in Centessa Pharmaceuticals in the third quarter worth $42,429,000. Bollard Group LLC bought a new stake in Centessa Pharmaceuticals in the second quarter worth $1,319,000. Finally, Ensign Peak Advisors Inc grew its stake in shares of Centessa Pharmaceuticals by 27.8% in the second quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock worth $7,355,000 after acquiring an additional 121,611 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.